Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice

Gastroenterology. 2010 Aug;139(2):574-85. doi: 10.1053/j.gastro.2010.04.043. Epub 2010 Apr 21.

Abstract

Background & aims: Commensal bacteria can activate signaling by the Toll-like and interleukin-1 receptors (TLR and IL-1R) to mediate pathogenesis of inflammatory bowel diseases and colitis-associated cancer. We investigated the role of the single immunoglobulin IL-1 receptor-related (SIGIRR) molecule, a negative regulator of TLR and IL-1R signaling, as a tumor suppressor to determine whether SIGIRR controls cell-cycle progression, genetic instability, and colon tumor initiation by modulating commensal TLR signaling in the gastrointestinal tract.

Methods: We analyzed adenomatous polyposis coli (Apc)min/+/Sigirr-/- mice for polyps, microadenomas, and anaphase bridge index. Commensal bacteria were depleted from mice with antibiotics. Akt, mammalian target of rapamycin (mTOR), and beta-catenin pathways were examined by immunoblotting and immunohistochemistry. Loss of heterozygosity of Apc and expression of cytokines and proinflammatory mediators were measured by nonquantitative or quantitative polymerase chain reaction.

Results: Apcmin/+/Sigirr-/- mice had increased loss of heterozygosity of Apc and microadenoma formation, resulting in spontaneous colonic polyposis, compared with Apcmin/+/Sigirr+/+ mice. The increased colonic tumorigenesis that occurred in the Apcmin/+/Sigirr-/- mice depended on the presence of commensal bacteria in the gastrointestinal tract. Cell proliferation and chromosomal instability increased in colon crypt cells of the Apcmin/+/Sigirr-/- mice. Akt, mTOR, and their substrates were hyperactivated in colon epithelium of Apcmin/+/Sigirr-/- mice in response to TLR or IL-1R ligands. Inhibition of the mTOR pathway by rapamycin reduced formation of microadenomas and polyps in the Apcmin/+/Sigirr-/- mice.

Conclusions: SIGIRR acts as a tumor suppressor in the colon by inhibiting TLR-induced, mTOR-mediated cell-cycle progression and genetic instability.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenomatous Polyposis Coli / genetics
  • Adenomatous Polyposis Coli / metabolism*
  • Adenomatous Polyposis Coli / microbiology
  • Adenomatous Polyposis Coli / pathology
  • Adenomatous Polyposis Coli / prevention & control*
  • Animals
  • Blotting, Western
  • Cell Proliferation
  • Chromosomal Instability
  • Colon / drug effects
  • Colon / metabolism*
  • Colon / microbiology
  • Colon / pathology
  • Cytokines / metabolism
  • Genes, APC*
  • Genes, Tumor Suppressor*
  • Immunohistochemistry
  • Inflammation Mediators / metabolism
  • Intestinal Mucosa / metabolism
  • Intracellular Signaling Peptides and Proteins / antagonists & inhibitors
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Loss of Heterozygosity
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Mutant Strains
  • Protein Kinase Inhibitors / pharmacology
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, Interleukin-1 / deficiency*
  • Receptors, Interleukin-1 / genetics
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases
  • Toll-Like Receptors / metabolism
  • Tumor Burden
  • beta Catenin / metabolism

Substances

  • CTNNB1 protein, mouse
  • Cytokines
  • Inflammation Mediators
  • Intracellular Signaling Peptides and Proteins
  • Protein Kinase Inhibitors
  • Receptors, Interleukin-1
  • SIGIRR protein, mouse
  • Toll-Like Receptors
  • beta Catenin
  • mTOR protein, mouse
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • Sirolimus